Organogenesis misses Q2 revenue estimates

Organogenesis Holdings

07/08/2025 21:13

Overview

Organogenesis Q2 2025 rev falls 23%, missing analyst expectations, per LSEG data

Adjusted net loss for Q2 2025 was $7.5 mln, compared to $0.2 mln income in Q2 2024

Adjusted EBITDA loss of $3.6 mln in Q2 2025, down from $15.6 mln income in Q2 2024

Outlook

Organogenesis expects 2025 revenue between $480 mln and $510 mln

Company forecasts 2025 net income between $(6.4) mln and $16.4 mln

Organogenesis anticipates 2025 adjusted EBITDA between $31.1 mln and $61.9 mln

Company sees 2025 Surgical & Sports Medicine revenue growing 6% to 23%

Result Drivers

ADVANCED WOUND CARE DECLINE - Revenue from Advanced Wound Care products fell 25% compared to Q2 2024

SURGICAL & SPORTS MEDICINE GROWTH - Revenue from Surgical & Sports Medicine products increased 16% year-over-year

OPERATING EXPENSES REDUCTION - Operating expenses decreased by 21% compared to Q2 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$100.80 mln
$103.40 mln (3 Analysts)
Q2 Adjusted Net Income
Miss
-$7.50 mln
-$3.40 mln (3 Analysts)
Q2 Net Income
-$9.40 mln
Q2 Adjusted EBITDA
Miss
-$3.60 mln
$1.40 mln (2 Analysts)
Q2 Operating Income
-$12.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Organogenesis Holdings Inc is $7.00, about 35.7% above its August 6 closing price of $4.50

The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 61 three months ago

Press Release: ID:nGNX3XRfSr

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)